SHROOM2

Across TCGA pan-cancer cohorts, SHROOM2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SHROOM2 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SHROOM2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SHROOM2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where SHROOM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	0.667	0.332	.015	10	view →
CCRCC	DFS	Tertile	IV	0.213	0.887	.024	6	view →
HNSC	DFS	Median	II,III,IV	0.736	0.563	.025	4	view →
UCEC	OS	Quartile	All	1.000	0.874	.031	4	view →
LSCC	DFS	Quartile	III,IV	1.000	0.771	.034	2	view →
PDAC	OS	Quartile	II,III,IV	0.280	0.419	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SHROOM2–LUAD (OS)

Open the LUAD breakdown →